Celcuity Projects $2.5B Peak Revenue for Gedatolisib. Celcuity has outlined ambitious revenue projections for its lead candidate gedatolisib, forecasting potential peak annual sales of $2.5 billion as the company advances through critical clinical and regulatory milestones. During its fourth quarter 2025 earnings call, management detailed the trajectory toward commercialization, highlighting the drug's pathway to market approval. The company's New Drug Application has received priority review status from the FDA, accelerating the evaluation timeline considerably. The pivotal VIKTORIA-1 clinical trial has generated compelling data supporting the therapeutic potential of gedatolisib in its target indication. Management outlined comprehensive commercial launch preparations, positioning the organization to capitalize on market opportunities upon approval.
